Clinical Trials Logo

Scabies clinical trials

View clinical trials related to Scabies.

Filter by:

NCT ID: NCT05198947 Completed - Scabies Clinical Trials

Better Disease Control by Multidrug Regimen in Scabies

Start date: January 2017
Phase: N/A
Study type: Interventional

Scabies is associated with significant discomfort and social taboo. Existing treatment regimen frequently fails due to lack of patient compliance. We compared single use regimen to existing standard repeat application regimen for treatment of scabies.

NCT ID: NCT05117528 Completed - Clinical trials for Microbial Colonization

Streptococcus Pyogenes Carriage Acquisition and Transmission Study

SpyCATS
Start date: July 27, 2021
Phase:
Study type: Observational

Group A Streptococcus (GAS) is a bacteria which causes severe infections and leads to deadly diseases such as rheumatic heart disease which kills over 300,000 people a year globally, particularly in low-income countries. It is not know how GAS is spread between people, how often people carry GAS in their throat or on their skin without having symptoms, or what factors increase the chance of this occurring. It is important to understand these factors in order to know how to reduce GAS-related disease. This study will follow 444 people in The Gambia, over 12 months, taking samples from the throats and skin of people living in the same households, and asking questions about themselves and their behaviour, at regular intervals. By taking samples over time, the investigators hope to understand how common it is to carry GAS without having symptoms, how GAS is spread between people, and whether carrying GAS leads to more GAS infections in people or their household members. The study will use state-of-the-art techniques to look at the DNA of GAS bacteria that we find, and combine this with a mathematical model to investigate how different strains spread to people within and between households in the community.

NCT ID: NCT05025696 Completed - Scabies Clinical Trials

Efficacy and Side Effects of Blacksoap® as Adjuvant Therapy of Scabies

Start date: September 18, 2018
Phase: N/A
Study type: Interventional

Background: Scabies is a skin disease due to Sarcoptes scabiei. The transmission risk is high among communities living together, such as dormitories, boarding schools, nursing homes, and so on. Blacksoap® is a soap product that is recognized as adjuvant therapy. Until now, there has been no research on the effectiveness and side effects of using Blacksoap®. Purpose: This research aimed to assess the cure rate of standard scabies treatment, with and without Blacksoap®, to determine pruritus visual analog scale (VAS) score, transepidermal water loss (TEWL) score before and after receiving therapy, and to evaluate the side effects of the treatment. Methods: The intervention group obtained standard therapy and Blacksoap®; meanwhile, the control group received standard therapy and baby soap.

NCT ID: NCT04931680 Recruiting - Scabies Clinical Trials

Risk Factors for Treatment Failure of Scabies in Autochthonous Populations of French Guiana (GUYAGALE)

GUYAGALE
Start date: March 29, 2021
Phase:
Study type: Observational

Scabies is a Neglected Tropical Disease, particularly important in autochthonous populations. Treatment failures could explain the high prevalence of this disease in Amerindian and Maroon populations of French Guiana. Our main objective is to look for specific sociodemographic risk factors for treatment failure of scabies in the remote areas of French Guiana. A secondary objective is to evaluate the prevalence of scabies and its complications.

NCT ID: NCT04844905 Recruiting - Malaria,Falciparum Clinical Trials

Adjunctive Ivermectin Mass Drug Administration for Malaria Control

MATAMAL
Start date: May 3, 2021
Phase: Phase 3
Study type: Interventional

This is a cluster-randomized placebo-controlled clinical trial to evaluate the additive benefit of Ivermectin (IVM) (or Placebo) mass drug administration (MDA) to dihydroartemisinin-piperaquine (DP) MDA for malaria control in a moderate to low malaria-endemic setting as an adjunctive strategy to existing programmatic malaria control measures. The regime of DP and IVM will target both human reservoirs of Plasmodium falciparum and the Anopheles gambiae vector respectively, with the aim of interrupting transmission. The trial will be conducted on the Bijagos Archipelago, where islands (clusters) will be randomised to receive seasonal DP and IVM or DP and Placebo MDA. The primary outcome will be the prevalence of infection with Plasmodium falciparum in all age groups detected by nucleic acid amplification testing during the peak malaria transmission season after two years of intervention.

NCT ID: NCT04814511 Recruiting - Scabies Clinical Trials

Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin)

ETSKABI
Start date: June 11, 2021
Phase: Phase 3
Study type: Interventional

The ETSKABI study is a prospective, open-label, multicenter, initially single-armed and in case of treatment failure subsequently three-armed randomized clinical trial. Within the initial treatment phase, the to-date clinical efficacy of the standard therapy regimen according to the current German "S1-guideline for the diagnosis and treatment of scabies" is to be examined. The subsequent second phase focusses on three differently escalated treatment regimens in order to evaluate their potential to cure those patients still suffering from Scabies after standard therapy. In total, 183 patients with Scabies who meet all inclusion criteria and do not meet none of the exclusion criteria are to be enrolled and topically treated with Permethrin 5 % cream (up to two administrations, i.e. repeated one-time on day 14 in case of persisting Scabies). In case of treatment failure by the end of phase one, adult patients will be randomized to either receive an (i) escalated therapy with Permethrin 5 % cream (repeated topical administration on two consecutive days), (ii) an add-on-combination consisting of escalated therapy with Permethrin 5 % cream and Ivermectin p.o. or (iii) an escalated therapy with Permethrin 10 % cream (up to two administrations, i.e. repeated one-time on day 14 in case of persisting Scabies). The primary objective of the ETSKABI study is the clinical efficacy of the standard therapy by the end of phase one (standard therapy according to the S1-guideline). Beside this, clinical efficacy by the end of phase two (escalation phase) will be evaluated as well as adverse events in order to investigate over-all clinical safety.

NCT ID: NCT04332068 Recruiting - Scabies Clinical Trials

Ivermectin Safety in Small Children

ISSC
Start date: November 18, 2023
Phase: Phase 2
Study type: Interventional

This trial will evaluate the safety, pharmacokinetics, and efficacy of ivermectin in scabies infected children weighing 5 to less than 15kg. This will allow future efforts to expand the indication of ivermectin treatment to infants weighing 5 to less than 15kg to treat numerous NTDs, allowing this young age group equitable access to the numerous benefits of ivermectin therapy.

NCT ID: NCT04205669 Completed - Scabies Clinical Trials

Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon

Start date: October 4, 2018
Phase: Phase 4
Study type: Interventional

It is unclear whether individual treatment of scabies is similarly effective compared to household treatment. This study therefore compares these two treatment strategies with topical benzyl benzoate for treating scabies in Lambaréné and surroundings in Gabon. Subjects presenting with uncomplicated scabies are randomized into either the Individual Treatment group, where only the affected subjects receive treatment, or the Household Treatment group, where all family members are treated in parallel to the affected subjects regardless of signs and symptoms. The primary endpoint is clinical cure after 28 days; the secondary endpoint is the proportion of affected household members per household after 28 days.

NCT ID: NCT03973775 Completed - Scabies Clinical Trials

A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimiteā„¢ in Subjects With Scabies

Start date: April 10, 2018
Phase: Phase 3
Study type: Interventional

This phase III study was conducted to establish the clinical bioequivalence of Permethrin Cream 5% and Elimiteā„¢ in the treatment of scabies following a single application.

NCT ID: NCT03905265 Completed - Scabies Clinical Trials

Dose-finding Study of Moxidectin for Treatment of Scabies

Start date: January 13, 2020
Phase: Phase 2
Study type: Interventional

The effective dose of moxidectin to treat human scabies is not known. This study aims to provide proof of concept that a single dose of moxidectin is effective in eliminating the scabies parasite in humans and to enable the determination of an optimal dose of moxidectin for treatment of scabies for further clinical studies.